Published in Mol Cell Proteomics on February 11, 2013
Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet (2014) 1.73
Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics. Chem Rev (2015) 0.88
Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease. Anal Chem (2014) 0.84
Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin Proteomics (2014) 0.83
Site-specific analysis of changes in the glycosylation of proteins in liver cirrhosis using data-independent workflow with soft fragmentation. Anal Bioanal Chem (2016) 0.78
The glycan role in the glycopeptide immunogenicity revealed by atomistic simulations and spectroscopic experiments on the multiple sclerosis biomarker CSF114(Glc). Sci Rep (2015) 0.76
Protein Microarrays with Novel Microfluidic Methods: Current Advances. Microarrays (Basel) (2014) 0.75
Lectins, Interconnecting Proteins with Biotechnological/Pharmacological and Therapeutic Applications. Evid Based Complement Alternat Med (2017) 0.75
Intracellular functions of N-linked glycans. Science (2001) 8.39
On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta (1999) 7.38
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell (2010) 3.60
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res (1983) 3.15
Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem (2001) 2.85
Monoclonal antibodies specific for human monocytes, granulocytes and endothelium. Immunology (1984) 2.82
Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep (2006) 2.82
Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology (2011) 2.56
Metabolism, cell surface organization, and disease. Cell (2009) 2.41
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
N-Glycans in cancer progression. Glycobiology (2008) 2.35
Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research. Nat Chem (2009) 2.09
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 1.99
Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics (2008) 1.94
Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res (1989) 1.93
Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines. Nat Methods (2011) 1.92
Biological function of fucosylation in cancer biology. J Biochem (2008) 1.91
Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem (2009) 1.82
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
Mass spectrometry in the analysis of N-linked and O-linked glycans. Curr Opin Struct Biol (2009) 1.77
Tumor-associated carbohydrate antigens. Annu Rev Immunol (1984) 1.76
The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer (2006) 1.67
Location, location, location: new insights into O-GalNAc protein glycosylation. Trends Cell Biol (2010) 1.65
Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem (2003) 1.63
The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl (2011) 1.60
Mass spectrometry based glycoproteomics--from a proteomics perspective. Mol Cell Proteomics (2010) 1.55
O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia (2001) 1.43
Glycan labeling strategies and their use in identification and quantification. Anal Bioanal Chem (2010) 1.43
Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc (2012) 1.40
Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol (1998) 1.40
Determination of site-specific glycan heterogeneity on glycoproteins. Nat Protoc (2012) 1.38
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res (1986) 1.36
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst (2009) 1.31
MUC1: a target molecule for cancer therapy. Cancer Biol Ther (2007) 1.30
Mouse monoclonal antibody F-3 recognizes the difucosyl type-2 blood group structure. Immunogenetics (1983) 1.27
Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res (1986) 1.26
Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem (2012) 1.26
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res (2011) 1.25
Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci (2011) 1.24
Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization. Int J Cancer (1987) 1.23
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene (2010) 1.23
The monoclonal antibody directed to difucosylated type 2 chain (Fuc alpha 1 leads to 2Gal beta 1 leads to 4[Fuc alpha 1 leads to 3]GlcNAc; Y Determinant). J Biol Chem (1983) 1.20
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res (2011) 1.20
Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis (2012) 1.19
Glycoproteomic analysis of antibodies. Mol Cell Proteomics (2013) 1.19
Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J Cell Mol Med (2012) 1.19
On-line separations combined with MS for analysis of glycosaminoglycans. Mass Spectrom Rev (2009) 1.19
Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics (2010) 1.16
Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics (2013) 1.11
Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem (1999) 1.11
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics (2009) 1.09
Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim Biophys Acta (1999) 1.09
Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics (2013) 1.09
Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene. Cancer Epidemiol Biomarkers Prev (2005) 1.08
Sweet and sour: the impact of sugars on disease. Rheumatology (Oxford) (2008) 1.08
Monoclonal antibodies against oncofetal mucin M1 antigens associated with precancerous colonic mucosae. Cancer Res (1986) 1.07
Tandem 18O stable isotope labeling for quantification of N-glycoproteome. J Proteome Res (2010) 1.07
Microarrays in glycoproteomics research. Clin Lab Med (2009) 1.07
Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res (2009) 1.05
Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis (2008) 1.05
Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer (2012) 1.05
Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. Anticancer Agents Med Chem (2008) 1.04
Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry. Glycobiology (2006) 1.04
Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search. J Proteome Res (2012) 1.04
Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomarkers Prev (2012) 1.02
cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Lett (1995) 1.02
The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj J (2012) 1.02
A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. Glycobiology (2009) 1.01
Large-scale identification of N-glycosylated proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB. J Proteome Res (2012) 0.99
Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics (2011) 0.95
A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics (2012) 0.95
Using lectins to harvest the plasma/serum glycoproteome. Electrophoresis (2012) 0.94
Carbohydrate antigens in human cancer. Cancer Surv (1985) 0.94
Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics (2012) 0.94
Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics (2012) 0.94
Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res (1990) 0.93
hCG, five independent molecules. Clin Chim Acta (2011) 0.93
Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci U S A (2010) 0.93
Quantification of glycopeptides by multiple reaction monitoring liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2012) 0.92
Breast cancer screening and biomarkers. Methods Mol Biol (2009) 0.92
Glycosylation of prostate specific antigen and its potential diagnostic applications. Clin Chim Acta (2012) 0.91
A fluorescent lectin array using supramolecular hydrogel for simple detection and pattern profiling for various glycoconjugates. J Am Chem Soc (2006) 0.91
Chemoenzymatic probes for detecting and imaging fucose-α(1-2)-galactose glycan biomarkers. J Am Chem Soc (2012) 0.91
CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer (2001) 0.90
Hepatocellular carcinoma. Curr Opin Gastroenterol (2004) 0.90
Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol (2011) 0.89
The human epithelial carcinoma antigen recognized by monoclonal antibody AE3 is expressed on a sulfoglycolipid in addition to neoplastic mucins. Biochem Biophys Res Commun (2011) 0.89
Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One (2011) 0.89
MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med (2004) 0.88
Mass spectrometry for congenital disorders of glycosylation, CDG. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.87
Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J Hepatol (2000) 0.87
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J (2012) 0.87
Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energy-resolved oxonium ion monitoring. Anal Chem (2012) 0.86
Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen. Tumour Biol (1991) 0.85
A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol (2005) 2.41
The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells. Cancer Res (2007) 1.55
Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics (2006) 1.36
Analysis of mass spectral serum profiles for biomarker selection. Bioinformatics (2005) 1.30
Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta (2012) 1.20
Associations between cigarette smoking and mitochondrial DNA abnormalities in buccal cells. Carcinogenesis (2008) 1.13
Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res (2008) 1.12
Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics (2013) 1.11
Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res (2010) 1.10
Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics (2013) 1.09
Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search. J Proteome Res (2012) 1.04
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics (2013) 1.03
Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. J Proteome Res (2013) 0.99
Acrolein-derived DNA adduct formation in human colon cancer cells: its role in apoptosis induction by docosahexaenoic acid. Chem Res Toxicol (2009) 0.93
Delineating diseases by IMS-MS profiling of serum N-linked glycans. J Proteome Res (2011) 0.92
Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes. PLoS One (2012) 0.89
Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma. Dis Markers (2010) 0.89
Mass spectrometric study of N-glycans from serum of woodchucks with liver cancer. Rapid Commun Mass Spectrom (2009) 0.88
Quantification of DNA repair capacity in whole blood of patients with head and neck cancer and healthy donors by comet assay. Mutat Res (2007) 0.88
Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers. Pac Symp Biocomput (2008) 0.87
Structure-based comparative analysis and prediction of N-linked glycosylation sites in evolutionarily distant eukaryotes. Genomics Proteomics Bioinformatics (2013) 0.86
Lung cancer in humans is not associated with lifetime total alcohol consumption or with genetic variation in alcohol dehydrogenase 3 (ADH3). J Nutr (2003) 0.85
Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. J Proteome Res (2014) 0.85
Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease. Anal Chem (2014) 0.84
Glycomic Alterations in the Highly-abundant and Lesser-abundant Blood Serum Protein Fractions for Patients Diagnosed with Hepatocellular Carcinoma. Int J Mass Spectrom (2011) 0.83
LC-MS3 quantification of O-glycopeptides in human serum. Electrophoresis (2013) 0.82
Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs. Int J Otolaryngol (2010) 0.82
Protein and site specificity of fucosylation in liver-secreted glycoproteins. J Proteome Res (2014) 0.81
Integrated peptide and glycan biomarker discovery using MALDI-TOF mass spectrometry. Conf Proc IEEE Eng Med Biol Soc (2008) 0.78
Ant colony optimization for biomarker identification from MALDI-TOF mass spectra. Conf Proc IEEE Eng Med Biol Soc (2006) 0.77
MS/MS library facilitated MRM quantification of native peptides prepared by denaturing ultrafiltration. Proteome Sci (2012) 0.76
Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2. J Biomol Struct Dyn (2014) 0.76
Analysis of peptides by denaturing ultrafiltration and LC-MALDI-TOF-MS. Methods Mol Biol (2013) 0.75
Urinary estrogen metabolites and prostate cancer risk: a pilot study. Prostate (2010) 0.75
A sensitive immunofluorescence assay for detection of p53 protein in the sputum. Methods Mol Med (2003) 0.75